Journal article
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nature medicine, Vol.29(9), pp.2259-2267
09/2023
DOI: 10.1038/s41591-023-02528-9
PMCID: PMC10504075
PMID: 37582952
Abstract
Abstract Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders switched to biweekly dosing. Results from cohort A, which enrolled patients without prior BCMA-directed therapy ( n = 123) are reported. The primary endpoint of confirmed objective response rate (ORR) by blinded independent central review was met with an ORR of 61.0% (75/123); 35.0% ≥complete response. Fifty responders switched to biweekly dosing, and 40 (80.0%) improved or maintained their response for ≥6 months. With a median follow-up of 14.7 months, median duration of response, progression-free survival and overall survival (secondary endpoints) have not been reached. Fifteen-month rates were 71.5%, 50.9% and 56.7%, respectively. Common adverse events (any grade; grade 3–4) included infections (69.9%, 39.8%), cytokine release syndrome (57.7%, 0%), anemia (48.8%, 37.4%), and neutropenia (48.8%, 48.8%). With biweekly dosing, grade 3–4 adverse events decreased from 58.6% to 46.6%. Elranatamab induced deep and durable responses with a manageable safety profile. Switching to biweekly dosing may improve long-term safety without compromising efficacy. ClinicalTrials.gov identifier: NCT04649359 .
Details
- Title: Subtitle
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
- Creators
- Alexander M. Lesokhin - Memorial Sloan Kettering Cancer CenterMichael H. Tomasson - University of IowaBertrand Arnulf - Hôpital Saint-LouisNizar J. Bahlis - University of CalgaryH. Miles PrinceRuben Niesvizky - NewYork–Presbyterian HospitalPaula Rodrίguez-OteroJoaquin Martinez-Lopez - Hospital Universitario 12 De OctubreGuenther Koehne - Miami Heart Research InstituteCyrille Touzeau - Centre Hospitalier Universitaire de NantesYogesh Jethava - Indiana Cancer ConsortiumHang Quach - The University of MelbourneJulien Depaus - UCLouvainHisayuki Yokoyama - Tohoku UniversityAfshin Eli Gabayan - Beverly Hills Cancer CenterDon A. Stevens - Norton HealthcareAjay K. Nooka - Piedmont Cancer InstituteSalomon Manier - Université de LilleNoopur Raje - Massachusetts General HospitalShinsuke Iida - Nagoya City UniversityMarc-Steffen Raab - University Hospital HeidelbergEmma Searle - The Christie HospitalEric Leip - Pfizer (United States)Sharon T. Sullivan - Pfizer (United States)Umberto Conte - Pfizer (United States)Mohamed Elmeliegy - Pfizer (United States)Akos Czibere - Pfizer (United States)Andrea Viqueira - Pfizer (Spain)Mohamad Mohty - Hôpital Saint-Antoine
- Resource Type
- Journal article
- Publication Details
- Nature medicine, Vol.29(9), pp.2259-2267
- DOI
- 10.1038/s41591-023-02528-9
- PMID
- 37582952
- PMCID
- PMC10504075
- NLM abbreviation
- Nat Med
- ISSN
- 1078-8956
- eISSN
- 1546-170X
- Grant note
- DOI: 10.13039/100004319, name: Pfizer
- Language
- English
- Electronic publication date
- 08/15/2023
- Date published
- 09/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Health, Sport, and Human Physiology ; Internal Medicine
- Record Identifier
- 9984455656302771
Metrics
39 Record Views